We have recently begun enrolling patients in a Phase 1 #ClinicalTrial with a new #oncology candidate. PTX-35 is an antibody that targets an entirely novel receptor involved in the immune response to #cancer.
clinicaltrials.gov/ct2/show/NCT04430348
clinicaltrials.gov/ct2/show/NCT04430348